Swiftsure International Inc.
Holmes Biopharma, Inc. : Largest Single Contract to Date

Holmes Biopharma Inc. / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma, Inc. :  Largest Single Contract to Date

Scottsdale, Arizona – January 07, 2008 – Holmes Biopharma, Inc. (Berlin
Stock Exchange Symbol HHJA, security code AOKDRX) is pleased to announce
the signing of a $1.6 million contract with a major biotech company for
conducting a Phase 1 trial at the company’s facility in Omaha Nebraska. 
This is the largest single contract signed to date, and brings the total of
committed contracts in 2007 to $13 million.

'This large contract and our first years sales results are evidence that
our aggressive growth strategy for 2008 is well under way, and reaffirms
the confidence our clients have in our clinical research work,' stated John
Metcalfe, CEO of Holmes Biopharma Inc..

About Holmes:
Holmes Biopharma Inc. and it’s wholly owned subsidiary, Qualia Clinical
Service, Inc.  is a contract research organization focused on providing
integrated and cost effective clinical development services. Currently,
clinics operate in Omaha, Nebraska USA, Toronto, Canada. and Kiev, Ukraine,
Eastern Europe. For more information about the company please visit our
website at www.holmesbiopharma.com.


On behalf of the Board of Directors 

John F. Metcalfe, President, CEO

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:
www.holmesbiopharma.com
Tel: 1-800-778-4990 Email: ir@holmesbiopharma.com
8655 East Via De Ventura, G-200, Scottsdale AZ 85258
09.01.2008  Financial News transmitted by DGAP
----------------------------------------------------------------------